Background. A significant waning of enterovirus 71 (EV71) antibody titer after priming immunization with an inactivated EV71 vaccine implied the potential need for a booster dose.
Since enterovirus type 71 (EV71) was first isolated in 1969 [1] , it has been associated with many outbreaks in several countries and regions around the Asia-Pacific region and has resulted in thousands of deaths [2] [3] [4] [5] [6] [7] [8] . Since 2008, hand, foot, and mouth disease cases associated with EV71 were widely reported in mainland China each year, giving rise to an important public health problem [9] . Therefore, developing an effective vaccine against EV71 is a high priority for those highprevalence areas.
In a previous phase 2 clinical trial (clinical trials registration NCT01399853), participants were recruited in August 2011 to evaluate the immunogenicity and safety of an inactivated EV71 vaccine. A significant waning of vaccine-elicited EV71 antibody titer during the first 6 months after 2 vaccinations was noticed [10] . On the basis of historical experience with inactivated poliovirus vaccine, a significant decline in antibody titer against poliovirus was also observed after primary series of vaccinations [11] . To keep better long-term antibody persistence, the World Health Organization (WHO) recommended a primary series followed by boost immunizations, which was used in many countries [12] [13] [14] [15] . The fast decline of EV71 antibody may also indicate a potential need for a booster dose of EV71 vaccine.
Thus, we conducted a clinical trial to evaluate the immunogenicity and safety of a booster dose of EV71 vaccine 1 year after the 2-dose priming immunization on the basis of the early phase 2 clinical trial.
METHODS

Study Design and Participants
In November 2012, we performed a randomized, double-blind, placebo-controlled trial in Donghai County, Jiangsu Province, China. This trial was conducted using a cohort of healthy children created in the early phase 2 clinical trial with EV71 vaccines, all of whom were aged 6-35 months. Participants in that cohort who had received at least 1 dose of EV71 vaccine in any formulations (160 U, 320 U, and 640 U with alum adjuvant or 640 U without adjuvant) composed the target population for recruitment in this booster immunization trial. Exclusion criteria were as follows: participants' guardians did not provide informed consent, acute febrile disease was present on the day of recruitment, acute infection due to any cause was present during the week before recruitment, any inactivated vaccine was received during the week before recruitment, any live attenuated vaccine was received during the 2 weeks before recruitment, and any medical history of laboratory-confirmed EV71-associated disease, of allergy to any vaccination or drug, of allergy to any ingredient in the inactivated EV71 vaccine, and/or of seizures or other common contraindicating conditions was present. The eligibility of participants was assessed through medical history inquiry and physical examination by investigators.
The study was approved by the ethics committee of the Jiangsu Provincial Center for Disease Control and Prevention (JSCDC) and performed by investigators from the JSCDC in accordance with the Declaration of Helsinki of the World Medical Association and with good clinical practice. Written informed consent was obtained from the guardians of each participant.
Randomization and Masking
Eligible participants were first classified into 4 formulation groups (EV71 vaccine of 160 U with adjuvant, 320 U with adjuvant, 640 U with adjuvant, or 640 U without adjuvant), according to the formulation of priming EV71 vaccine they had received in the early phase 2 trial, and were then rerandomized to receive either a booster dose in accordance with the priming dose of EV71 vaccines or placebo in a ratio of 2:1 within each formulation group. The randomization list (block size, 6) was prepared by an independent statistician, using SAS, version 9.1 (SAS Institute, Cary, NC). The 4 vaccine formulations and placebo had identical packaging and were labeled with a unique identification number. Those who were involved in the procedure of randomization and masking did not take part in any other process of the trial. Allocation of treatment was masked from all participants, their guardians, and investigators during the whole study.
Procedures
Inactivated EV71 vaccines for booster immunization were developed by Beijing Vigoo Biological (Beijing, China), using EV71 strain FY7VP5/AH/CHN/2008 (subgenotype C4) as the seed virus (GenBank accession number JX025561). The same formulations of EV71 vaccines that had been tested in the previous phase 2 clinical trial were used, including 1 adjuvant-free vaccine formulation containing 640 U of EV71 antigen with 1.0 µg of total protein and 3 alum-adjuvant vaccines containing 160 U, 320 U, and 640 U of EV71 antigen with 0.25 µg, 0.5 µg, and 1.0 µg, respectively, of total protein and 0.18 mg of aluminum hydroxide per dose [10] . The placebo contained 0.18 mg of aluminum hydroxide without EV71 antigen.
After randomization in this trial, participants received 1 booster injection intramuscularly to the deltoid muscle, which occurred around 1 year after receipt of their priming EV71 immunization. After the booster dose, participants were observed for at least 30 minutes for immediate adverse events, and then participants' guardians were assigned to record the axillary temperature over the next 7 days, as well as any adverse events daily for 28 days after injection, on diary cards. Adverse events were graded according to the scale issued by China Food and Drug Administration [16] . We documented and assessed all serious adverse events during the study period.
Blood samples were collected immediately before and 28 days after injection and were subsequently shipped to the Chinese National Institute of Food and Drug Control for measurement of neutralizing antibody in sera, using a modified cytopathogenic effect assay and a neutralization antibody assay [17, 18] that was modified from the standard method developed by the WHO and used for the detection of the antibody against poliovirus [19] . The pre-and postvaccination serum specimens were serially diluted 2-fold with the detectable neutralizing antibody titer, which was expressed as the reciprocal of the serial dilution and ranged from 1:8 to 1:1024 and 1:8 to 1:16 384, respectively. All serum samples were blindly assayed and double-checked.
Statistics
Because the participants in this study were recruited from the cohort of a previous phase 2 trial, the sample size was constrained by the original cohort. However, a post-hoc sample size calculation by PASS software (version 8.0) indicated that, within each formulation groups, 93 participants (with 62 participants receiving a specific formulation of EV71 vaccine and 31 participants receiving placebo) would be enough to provide at least 90% power to reveal the difference in serological responses after the booster dose of vaccine and placebo.
The primary end point for immunogenicity assessment was the geometric mean titer (GMT) of EV71 neutralizing antibody that was induced by the booster dose of EV71 vaccine, whereas the secondary immunogenicity end points were seroconversion rate and geometric mean fold-increase (GMFI). EV71 neutralizing antibody titer was log-transformed for calculation of GMT, GMFI, and corresponding 95% confidence intervals (CIs). Titers lower than 1:8 were assigned a value of 1:4 before calculation. Seroconversion was defined as either at least a 4-fold titer rise or conversion from a prevaccination titer below 1:8 to a postvaccination titer of 1:32 or more. The proportion of participants with a postvaccination titer equal to or greater than 1:32 was also calculated. The primary analysis for immunogenicity was performed on the basis of an accordingto-protocol (ATP) cohort, consisting of children who had correctly received the priming 2-dose vaccinations in the previous phase 2 trial, received the booster dose in this complementary clinical trial 1 year later (±30 days), and had antibody titers both before and after booster injection serum available. For the safety assessment, the occurrence of injection-site and systemic adverse reactions within 28 days after vaccination were evaluated in the whole vaccinated population.
The χ 2 test or Fisher exact test was used for analyzing categorical data, and analysis of variance was used for the analysis of continuous data. When a significant difference among the participants receiving a booster shot of EV71 vaccines with 4 different formulations was found, multiple χ 2 comparisons, based on a Bonferroni-adjusted α value or findings of the StudentNewman-Keuls test, were used accordingly. Statistical analyses were performed by an independent statistician, using SAS, version 9.1, and the hypothesis tests were 2-sided, with an α value of 0.05.
RESULTS
A total of 844 participants in the cohort from the previous phase 2 trial were assessed in November 2012 for eligibility for this boost immunization clinical trial. Of these, 773 were enrolled and then classified into 4 formulation groups: 189 received 160 U with adjuvant (126 vaccine recipients vs 63 placebo recipients), 193 received 320 U with adjuvant (128 vs 65), 191 received 640 U with adjuvant (127 vs 64), and 200 received 640 U without adjuvant (133 vs 67; Figure 1 ). All 773 randomized participants received a booster injection and completed the 28-day safety follow-up. Serum samples were obtained from 771 participants (99.7%) immediately before the booster shot and from 722 (93.4%) 28 days after injection. The demographic characteristics of participants are summarized in Table 1 .
Immunogenicity
In total, 707 participants (91.5%) were eligible for the primary immunogenicity analysis in the ATP cohort, with 174, 180, and 171 participants receiving 160 U, 320 U, and 640 U with adjuvant, respectively, and 182 receiving 640 U without adjuvant ( Figure 1 and Supplementary Table 1 ). Within each formulation group, the prevaccination GMTs were not significantly different between participants receiving vaccine and those receiving placebo (Table 2) . Although the GMTs of EV71 antibody in participants before the booster dose (1 year after the priming 2-dose immunization with EV71 vaccines) were quite high (>138.2) in all of the vaccine groups, the groups that received 320 U and 640 U with adjuvant had remarkably higher Figure 1 . Trial profile. The reasons why 66 of 773 participants who enrolled and received the booster dose were not included in the according-to-protocol (ATP) cohort for immunogenicity analysis are listed in Supplementary Table 1 . Abbreviation: EV71, enterovirus 71.
GMTs than the group that received 640 U without adjuvant. A similar trend was also found in terms of the proportion of participants with a titer that was greater than or equal to 1:32 just before the booster vaccination. Twenty-eight days after the injection of booster dose, participants who received EV71 vaccine at each formulation showed a strong immune response, whereas those who received placebo showed almost no activation of immune response (Figure 2) . The highest GMTs after booster receipt were observed in the group that received 640 U with adjuvant (4410.7; 95% CI, 3565.6-5456.1), followed by the group that received 320 U with adjuvant (3352.5; 95% CI, 2779.1-4044.0), and the lowest were observed in the group that received 160 U with adjuvant (2352.6; 95% CI, 1959.0-2825.4) and 640 U without adjuvant (2214.8; 95% CI, 1844.2-2659.8; Table 2 and Supplementary  Figure 1) . The proportions of participants with an antibody titer of ≥1:32 before and after the booster dose were not significantly different between the groups that received 320 U with adjuvant (P = .3) or 640 U with adjuvant (P = .2). But the postvaccination proportions of participants with an antibody titer of ≥1:32 were statistically higher than the prevaccination proportions in the groups that received 160 U with adjuvant (P = .001) or 640 U without adjuvant (P = .0006). In terms of seroconversion rates and GMFIs, a booster dose of EV71 vaccine in any of the 4 formulations elicited strong antibody responses, whereas the placebos almost elicited no antibody response at day 28. The highest seroconversion rate, 92.1%, was observed in the participants who received 640 U with adjuvant, followed by those who received 320 U with adjuvant or 160 U with adjuvant; the lowest seroconversion rate was observed in participants who received 640 U without adjuvant. Similar results were also observed in the analysis with the intention-to-treat cohort for assessment of immunogenicity of the booster vaccine (Supplementary Table 2 ). Safety 220 of 773 participants (28.5%) reported at least 1 adverse reaction within 28 days after injection of the booster dose (Table 3) . The incidence of systemic reactions ranged from 23.9% (95% CI, 14.3%-35.9%) to 29.9% (22.1%-38.7%) in all vaccination groups. No statistical significance was found between the vaccine and placebo groups. The incidence of injection-site reactions was very low and comparable between participants receiving vaccine or placebo within each formulation group, and it was not dose dependent with the vaccine formulations. Fever was the most commonly reported systemic symptom (range, 21.4% [95% CI, 14.6%-29.6%] to 27.6% [95% CI, 20.0%-36.2%]) in participants who received vaccines in the 4 formulation groups, whereas pain was the most common injection-site symptom (3 cases in the group that received 160 U with adjuvant and 1 cases in the group that received 640 U with adjuvant; Table 3 ). No immediate allergic reaction within Seroconversion was defined as either a ≥4-fold increase in titer or change from a negative baseline titer (with a titer of less than 1:8) to a titer of 1:32 or more. The ATP population was defined as participants who had correctly received the priming 2-dose vaccinations in the previous phase 2 trial, who received the booster dose in this complementary clinical trial 1 year later (±30 days), and for whom antibody titers in serum both before and after booster injection were available.
Abbreviations: CI, confidence interval; GMFI, geometric mean fold increase; GMT, geometric mean titer. a From multiple comparisons analysis between participants who received booster EV71 vaccine within each formulation group. Multiple comparisons were used on the basis of an adjusted α = 0.0083 for rate or proportion. The Student-Newman-Keuls test was used for multiple comparisons analyses of GMTs and GMFIs. Different characters (ie, b, c, and d, after the 95% CIs of each group) were used to mark the differences (b > c > d) between each treatment group by multiple comparisons analyses. Table 3 continued. a Severity grades were defined as follows, unless otherwise indicated: grade 1, mild (ie, no interference with activity); grade 2, moderate (ie, some interference with activity); grade 3, severe (ie, prevented activity). b Grade 1, axillary temperature of 37.1°C-37.5°C; grade 2, axillary temperature of 37.6°C-39.0°C; grade 3: axillary temperature of ≥39.1°C.
Abbreviation: CI, confidence interval.
30 minutes after injection was observed. Most of the reported adverse reactions were mild or moderate, although 6 participants had a grade 3 fever reaction (highest temperature, >39.0°C). During the 28-day follow-up period, 1 placebo booster recipients from the group that received 640 U without adjuvant reported a severe adverse event involving hospitalization with scarlet fever onset on day 27 after the injection.
DISCUSSION
Currently, there are 5 EV71 vaccine candidates that have been tested in clinical trials, all of which are inactivated alumadjuvanted EV71 whole-virus vaccines, each with a different subgenotype strain. Of these 5 vaccine candidates, 3 have been evaluated in phase 3 trials in mainland China, and evaluations of the other 2 have been completed in phase 1 trials in Taiwan and Singapore [20, 21] . The EV71 vaccines have had a good safety profile, high immunogenicity, and significant efficacy against EV71-associated disease in 1-year follow-up after a priming immunization schedule of 2 doses 28 days apart in young children [22, 23] . But no data on the booster immunization of EV71 vaccine has ever been revealed. Data in this trial showed that a booster dose of any of the 4 formulations of EV71 vaccine induced excellent immunological responses in terms of postvaccination GMTs, seroconversion rates, and GMFIs, compared with the placebo groups. Comparisons among different formulations indicated that the EV71 vaccines of 640 U with alum adjuvant might elicit the strongest immune response. It was noted that the booster-dose effect was so strong that the postvaccination GMTs were 6-10 times higher than those after receipt of the priming 2-dose immunization on day 56. Even the less immunogenic vaccine formulation of 640 U without adjuvant induced a GMT of 2214.8 (95% CI, 1844.2-2659.8). However, the seroconversion rates after the booster dose (79.5%-92.1%) were not significantly different from those observed after the priming immunization (84.5%-97.3%) in the original trial before this study [10] . A titer of 1:32 was suggested as a surrogate of vaccine protection against EV71-associated diseases [22] , so the proportion of participants with a titer of ≥1:32 was also measured in this trial. However, the proportions of participants with a titer of ≥1:32 were around 100% among those who had received a booster dose of EV71 vaccine in any formulation. Because the addition of adjuvant could significantly spare vaccine by using a lower dose, we believe that the alum-adjuvant formulations with 160 U or 320 U should be appropriate for a booster dose.
The incidence of injection-site adverse reactions for vaccines in this trial was in line with that among children aged 12-36 months and significantly lower than that among infants aged 6-11 months (data not shown) in the early priming immunization phase 2 clinical trial. By contrast, the incidences of systemic adverse reactions or grade 3 fever were a little higher than those among participants aged 12-36 months in early priming immunization, but no statistically significant difference between vaccine and placebo was found, which might be attributable to the fact that these boost immunizations were administrated during the cold season.
In this study, participants were recruited from the original cohort associated with the phase 2 trial and therefore had already received the 2 initial vaccinations. Although the reuse of participants was logistically efficient, there were also some limitations. The study was constrained by maintaining the same formulation in the booster dose as that in the primary series of vaccinations for individuals in the original trial, which limited a completely independent assessment of the booster dose. Also, almost 10% of the participants were assessed but not enrolled in the trial, which might be a possible source of selection bias. Although a significant decline in the level of EV71 antibody was observed within the first half year after the primary series of vaccinations in the original trial, with GMTs decreasing from 509.0-1383.2 on day 56 to 58.8-177.4 at month 8 in the 4 vaccine formulation groups [10] . The GMTs of EV71 antibody at around 1 year after primary immunization (before receipt of the booster injection) showed that the decrease in antibody titer ceased during the next half year and remained stable thereafter, with the antibody titer for some participants even moderately increasing. Before the booster dose, GMTs of 138.2-264.3 were found, which were probably due to the subclinical infection caused by natural exposure to EV71 during the EV71 season. A similar dynamic tendency of EV71 antibody was also observed in a large-scale phase 3 clinical trial: the antibody titer of the participants who received EV71 vaccines stopped waning and remained quite stable during months 8-14, while that of the participants receiving placebo increased [22] . Thus, the real warning trend of vaccine-elicited antibody titer could be covered and distorted by a natural boosting effect attributable to the prevalence of EV71. In any case, the high GMTs and the proportion of participants with a titer greater than or equal to 1:32 suggested that vaccine-elicited antibody levels could persist for at least 1 year, and a boost immunization after 1 year may not be necessary in such a situation. Once the EV71 vaccine is approved for market, however, large-scale immunization with EV71 vaccine may block epidemics of EV71 infection and reduce the opportunity for natural exposure among children. In that case, the vaccine-elicited antibody titer may drop much faster than what we observed here, which calls for a booster dose, as does the immunization schedule for some other universally administrated vaccines, such as polio, pertussis, mumps, and measles vaccines [24] [25] [26] . Another limitation is that this booster immunization trial was conducted using the same vaccine formulations as the previous phase 2 trial. It is possible that these vaccine formulations may not represent the optimal formulation for booster injection: EV71 vaccines containing a smaller amount of antigen, with or without adjuvant, might be immunogenic enough as booster dose, which should be further evaluated.
Although the high prevaccination EV71 antibody level compromised, to some extent, the need for this booster immunization 1 year after the priming EV71 vaccinations, a booster dose of EV71 vaccine in any formulation had the ability to elicit a remarkable anamnestic response that may result in a long duration of antibody persistence and protect children from EV71-associated disease. In view of the potential for booster dose injection in future, especially after the approval of EV71 vaccine for market, continuous observation of the protection afforded by EV71 vaccines and the incidence of EV71-associated disease among vaccinated children should be performed.
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